Drug
Ebselen clinical trials
Also written SPI-1005 and PZ-51.
- studies test it
- 14
- open now
- 3
- in phase 3
- 3
- first study started
- 1999
Keep track of what changes. Save the ebselen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2006 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 3
Sound Pharmaceuticals, Incorporated (11) · University of Oxford (2) · Brigham and Women's Hospital (1)
Studies
Open first, then newest update. How each study uses ebselen is read from its arms, and is right about nine times in ten.
Testing it · 14
- SPI-1005 in Adults Receiving Cochlear ImplantRecruitingPhase 2Sound Pharmaceuticals, IncorporatedNCT06340633Written as Ebselen
- SPI-1005 Treatment in Moderate COVID-19 PatientsEnrolling by invitationPhase 2Sound Pharmaceuticals, IncorporatedNCT04484025Written as Ebselen
- IMPase in Treatment-resistant DepressionRecruitingPhase 1University of OxfordNCT05117710Written as Ebselen
- SPI-1005 for the Treatment of Meniere's DiseaseCompletedPhase 3Sound Pharmaceuticals, IncorporatedNCT04677972Written as Ebselen
- SPI-1005 for Prevention and Treatment of Tobramycin Induced OtotoxicityCompletedPhase 2Sound Pharmaceuticals, IncorporatedNCT02819856Written as SPI-1005 Ebselen 200mg Capsule x1
- SPI-1005 for the Treatment of Meniere's Disease (Open Label)Active, not recruitingPhase 3Sound Pharmaceuticals, IncorporatedNCT06859788Written as Ebselen
- SPI-1005 Treatment in Severe COVID-19 PatientsCompletedPhase 2Sound Pharmaceuticals, IncorporatedNCT04483973Written as Ebselen
- Study to Evaluate SPI-1005 in Adults With Meniere's DiseaseCompletedPhase 1/2Sound Pharmaceuticals, IncorporatedNCT02603081Written as SPI-1005
- A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing LossWithdrawnPhase 2Sound Pharmaceuticals, IncorporatedNCT02779192Written as SPI-1005 200mg
- SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing LossWithdrawnPhase 2Sound Pharmaceuticals, IncorporatedNCT01451853Written as SPI-1005 Low Dose
- SPI-1005 for the Treatment of Patients With Meniere's DiseaseCompletedPhase 2Sound Pharmaceuticals, IncorporatedNCT03325790Written as 200mg SPI-1005 BID
- Ebselen as an add-on Treatment in Hypo/ManiaCompletedPhase 2University of OxfordNCT03013400Written as Ebselen
- Study to Evaluate the Safety and Pharmacokinetics of SPI-1005CompletedPhase 1Sound Pharmaceuticals, IncorporatedNCT01452607Written as SPI-1005
- Signaling Mechanisms and Vascular Function in Patients With Diabetes MellitusCompletedPhase 2/3Brigham and Women's HospitalNCT00762671Written as Ebselen
As the comparator · 1 — what is tested is compared with ebselen
Codes
What other systems call ebselen · ClinicalTrials.gg INT003168
- MeSH (NLM) C042986ebselenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 40X2P7DPGHEBSELENConfirmed FDA, NLM, Wikidata
- Wikidata Q5332073ebselenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65503EbselenOne source FDA
- DrugBank DB12610One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C042986 | ebselen | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 40X2P7DPGH | EBSELEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5332073 | ebselen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65503 | Ebselen | One source FDA |
| DrugBank | DB12610 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.